Skip to main
CRIS

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis is positioned for success with its promising pipeline and financial stability. Its recent positive results and expanded readouts in the TakeAim CLL and PCNSL studies demonstrate the efficacy and potential of its therapies. With a strong financial position and ongoing partnerships and collaborations, Curis has the resources and support to continue its development efforts and drive value for shareholders.

Bears say

Curis is a biotechnology company with a negative outlook, as its pipeline products have not shown strong results in the past and the company will likely need additional funding to continue development. Additionally, the current valuation is based on optimistic assumptions and the stock faces risks from potential failures in clinical trials. The company's financials may also be impacted by the need for substantial additional capital.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.